Filings/CTMX/IR

CYTOMX THERAPEUTICS, INC. IR

financial tables

Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Source document

Issuer site
Loading document…
Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial — CYTOMX THERAPEUTICS, INC.